Bio-Techne is excited to participate in Spear Bio’s $45 million Series A funding round. Founded by Feng Xuan and Peng Yin, Spear Bio is a leader in the development and manufacture of ultra-sensitive immunoassays capable of measuring protein biomarkers at attomolar level from sub-microliter sample volume. Its technology is ideal for historically challenging low abundant biomarkers in neurology, inflammation and oncology. The initial offering will focus on key biomarkers supporting translational research in Alzheimer’s disease. Read more: https://lnkd.in/gY9KqgUa
Bio-Techne is excited to participate in Spear Bio’s $45 million Series A funding round. Founded by Feng Xuan and Peng Yin, Spear Bio is a leader in the development and manufacture of ultra-sensitive immunoassays capable of measuring protein biomarkers at attomolar level from sub-microliter sample volume. Its technology is ideal for historically challenging low abundant biomarkers in neurology, inflammation and oncology. The initial offering will focus on key biomarkers supporting translational research in Alzheimer’s disease. I can't wait to see how the Spear Bio team positively impacts human health!